15 years of revenue, profit, cash flow and balance-sheet history through FY2026,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 2.9% per year over the past 5 years.
Net income has grown in line with revenue (2.9% vs 2.9% per year).
Operating margin has contracted, at 28.4% in the latest year.
Free cash flow has grown 2.9% per year over the past 5 years.
Financial health
Total debt ($994M) exceeds cash ($64M); net debt is $930M.
Total debt has grown slower than revenue (-7.6% vs 2.9% per year).
Total debt is 2.9× EBITDA.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2026
$1.1B
$190M
54.7%
28.4%
10.1%
5.4%
$246M
$994M
$64M
2025
$1.1B
$215M
55.8%
29.6%
11.7%
6.3%
$243M
$992M
$98M
2024
$1.1B
$209M
55.5%
30.4%
12.6%
6.3%
$239M
$1.1B
$46M
2023
$1.1B
-$82M
55.4%
-2.0%
-5.7%
-2.5%
$222M
$1.3B
$58M
2022
$1.1B
$205M
57.1%
30.4%
13.0%
5.6%
$250M
$1.5B
$27M
2021
$943M
$165M
58.0%
31.5%
12.1%
4.8%
$213M
$1.5B
$32M
2020
$963M
$142M
57.3%
30.2%
12.2%
4.0%
$203M
$1.7B
$95M
2019
$976M
-$36M
56.9%
6.9%
-3.3%
-1.0%
$179M
$1.8B
$28M
2018
$1.0B
$340M
55.4%
20.7%
28.8%
9.0%
$198M
$2.0B
$33M
2017
$882M
$69M
56.7%
23.3%
8.4%
1.8%
$146M
$2.2B
$42M
2016
—
$100M
—
—
13.4%
3.4%
$173M
$1.6B
$27M
2015
—
$78M
—
—
12.5%
3.0%
$150M
$1.6B
$21M
2014
—
$73M
—
—
12.9%
4.0%
$109M
$934M
$28M
2013
—
$66M
—
—
13.7%
3.8%
$127M
$971M
$16M
2012
—
$37M
—
—
9.2%
2.1%
$67M
$1.1B
$19M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Jun '26
$266M
$29M
51.3%
19.8%
1.5%
0.6%
$67M
$2.0B
$89M
Mar '26
$282M
$54M
51.9%
26.8%
2.9%
1.5%
$38M
$994M
$64M
Dec '25
$283M
$47M
55.5%
29.1%
2.6%
1.3%
$75M
$1.0B
$62M
Sep '25
$274M
$42M
55.3%
29.1%
2.3%
1.2%
$55M
$993M
$119M
Jun '25
$250M
$47M
56.2%
28.8%
2.6%
1.4%
$78M
$993M
$140M
Mar '25
$297M
$50M
57.3%
29.8%
2.7%
1.5%
$58M
$992M
$98M
Dec '24
$290M
$61M
55.5%
31.7%
3.4%
1.8%
$64M
$992M
$51M
Sep '24
$284M
$54M
55.5%
29.7%
3.1%
1.6%
$68M
$1.1B
$52M
Jun '24
$267M
$49M
54.7%
27.0%
2.9%
1.5%
$54M
$1.1B
$34M
Mar '24
$277M
$49M
54.8%
29.7%
3.0%
1.5%
$64M
$1.1B
$46M
Dec '23
$283M
$53M
55.9%
30.7%
3.3%
1.6%
$69M
$1.2B
$64M
Sep '23
$286M
$54M
55.9%
30.8%
3.5%
1.6%
$60M
$1.3B
$60M
Jun '23
$279M
$53M
55.4%
30.5%
3.6%
1.6%
$47M
$1.3B
$55M
Mar '23
$286M
-$241M
53.8%
-98.3%
-16.6%
-7.2%
$56M
$1.3B
$58M
Dec '22
$276M
$52M
54.6%
31.6%
3.1%
1.4%
$53M
$1.4B
$86M
Sep '22
$289M
$51M
55.7%
29.2%
3.1%
1.4%
$55M
$1.4B
$42M
Jun '22
$277M
$55M
57.8%
31.4%
3.5%
1.5%
$57M
$1.5B
$36M
Mar '22
$267M
$52M
55.8%
29.0%
3.3%
1.4%
$60M
$1.5B
$27M
Dec '21
$274M
$50M
56.5%
30.1%
3.3%
1.4%
$64M
$1.5B
$21M
Sep '21
$276M
$45M
57.1%
28.4%
3.1%
1.2%
$58M
$1.6B
$43M
Valuation over time
How the market has priced PBH against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 16.2× (Apr '24) to 12.4× (Nov '26).
The price-to-sales ratio has fallen from 2.6× (Mar '23) to 2.2× (Nov '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is PBH growing its revenue and profit?
Over the past 5 years, Prestige Consumer Healthcare Inc.'s revenue has grown 2.9% per year, and net income grown 2.9% per year. These are computed facts, not advice.
How much debt does PBH have?
As of FY2026, Prestige Consumer Healthcare Inc. reported $994M of total debt against $64M of cash.
What is PBH's profit margin?
In FY2026, gross margin was 54.7%, operating margin 28.4%, and net margin 17.5%.
What is PBH's P/E ratio?
Prestige Consumer Healthcare Inc.'s P/E (TTM) is 13.70 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the PBH stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 12.4× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.